ClinicalTrials.gg
Not yet recruitingNCT07903506iMMagine-6Updated Nov 16, 2026

To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

A Phase 3 interventional study of Anitocabtagene Autoleucel and Isatuximab in Newly Diagnosed Multiple Myeloma, sponsored by Kite, A Gilead Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 3, Interventional, and Treatment

Updated Oct 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Multiple Myeloma by Gilead Sciences — 2 open to participants now, 5 under way, 3 of them phase 3. Multiple Myeloma · Gilead Sciences.

Planned enrollment
Largest of 14
750 · median 34
Started
2027
with 1 other
Phase 3
3 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Multiple Myeloma by Gilead Sciences, this one has the largest planned enrollment, is one of 2 that started in 2027, is one of 3 in phase 3, and was the 13th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

2 of the 14 studies in Multiple Myeloma by Gilead Sciences are open now. Recruiting first, the newest first:

All 2 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Multiple Myeloma by Gilead Sciences, or all of them as a file.
02

Study summary

The goal of this clinical study iMMagine-6 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus autologous stem cell transplant in participants with newly diagnosed multiple myeloma (NDMM).

The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel administered after quadruplet-based induction versus standard of care therapy (SOCT; quadruplet-based induction followed by autologous stem cell transplant (auto-SCT) in participants with NDMM who are eligible for auto-SCT.

Read the detailed description

After completing quadruplet-based induction therapy followed by anitocabtagene autoleucel or autologous stem cell transplant, participants in both treatment arms will receive maintenance therapy for up to 36 cycles.

After completing the maintenance treatment period, participants will continue in a follow-up period for disease assessment and outcomes.

03

Conditions studied

  • Newly Diagnosed Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • CAR-T
  • ddBCMA
  • BCMA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented NDMM according to IMWG diagnostic criteria
  • Considered to be transplant-eligible by the investigator
  • at screening per IMWG, defined as any of the following:

    1. Serum M-protein level ≥ 1.0 g/dL; or
    2. Urine M-protein level ≥ 200 mg/24 hours; or
    3. Serum free light chain (FLC) ≥ 10 mg/dL (100 mg/L) and abnormal serum FLC ratio
  • (ECOG) performance status of 0 or 1
  • Adequate organ function including hematological, renal, hepatic and cardiac with further details in protocol defined inclusion/exclusion criteria

Key Exclusion Criteria:

  • Any prior anti-multiple myeloma (MM) therapy (including B-cell maturation antigen (BCMA)-directed therapy, CAR T-cell therapy, or genetically modified cells), with the exception of protocol-specified anti-MM stabilizing therapy, radiotherapy for MM plasmacytoma(s), and palliative focal radiation
  • Central nervous system (CNS) or meningeal involvement of MM
  • Cardiac atrial or ventricular MM involvement
  • History of or active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis
  • Active (other than MM) requiring treatment for disease control within the last 24 months.
  • Prior stem cell transplant
  • Any prior systemic treatment or radiotherapy treatment for any cancer other than MM within 24 months before randomization.
  • ≤ 4 weeks before randomization
  • Presence or suspicion of infection that is uncontrolled
  • History or presence of intracranial or CNS disorders or malignant CNS neoplasms
  • Females who are pregnant or breastfeeding
  • Females of who are not willing to use a highly effective method of from the time of through the protocol-specified duration.
  • to fludarabine, cyclophosphamide, or melphalan
  • History of allergy or to any trial agent or trial drug components
  • \< 12 weeks

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
750 participants (estimated)

Study arms

  • Active comparator
    Arm A: Standard of Care Therapy (SOCT)

    Participants will receive a total of three induction therapy cycles, 42 days for each cycle, with isatuximab, bortezomib, lenalidomide and dexamethasone. Following induction, participants will receive high dose conditioning therapy with melphalan and autologous stem cell transplantation (auto-SCT). Following auto-SCT, participants will receive maintenance therapy with isatuximab and lenalidomide during 28-day cycles for up to 36 cycles or until unacceptable toxicity, disease progression per IMWG criteria, or withdrawal of consent, whichever occurs first.

    Drug: Isatuximab · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Melphalan

  • Experimental
    Arm B: Anitocabtagene Autoleucel

    Participants will receive a total of three induction therapy cycles, 42 days for each cycle, with isatuximab, bortezomib, lenalidomide and dexamethasone. Following induction, participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine for 3 days, followed by a single infusion of anitocabtagene autoleucel. Following anitocabtagene autoleucel, participants will receive maintenance therapy with isatuximab and lenalidomide during 28-day cycles for up to 36 cycles or until unacceptable toxicity, disease progression per IMWG criteria, or withdrawal of consent, whichever occurs first.

    Drug: Anitocabtagene Autoleucel · Drug: Isatuximab · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

06

What researchers measure

Primary outcomes

  1. Minimal Residual Disease (MRD)-Negative Complete Response (CR) or Stringent CR (sCR) Rate at 12 Months

    Minimal residual disease (MRD)-negative CR/sCR is defined as the proportion of participants achieving CR/sCR and MRD-negative status (10\^5 cutoff) at 12 months. CR/sCR per International Myeloma Working Group (IMWG) criteria is determined by the Independent Review Committee (IRC).

    Time frame: Up to 12 months

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented disease progression per International Myeloma Working Group (IMWG) criteria as determined by the Independent Review Committee (IRC), or death due to any cause, whichever occurs first.

    Time frame: Up to 15 years

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to 15 years

  2. Overall Response Rate (ORR)

    ORR is defined as the proportion of participants who achieve a best overall response of at least PR or better (sCR, CR, very good partial response (VGPR), or PR) per the 2016 IMWG criteria as determined by the IRC.

    Time frame: Up to 15 years

  3. Rate of Very Good Partial Response or Better

    Rate of VGPR or better is defined as the proportion of participants who achieve a best overall response of sCR, CR, or VGPR per the 2016 IMWG criteria as determined by the IRC.

    Time frame: Up to 15 years

  4. Rate of CR or Better

    Rate of CR or better is defined as the proportion of participants who achieve a best overall response of CR or sCR per the 2016 IMWG criteria as determined by the IRC.

    Time frame: Up to 15 years

  5. Time to Response (TTR)

    TTR is defined as the time from date of randomization to the earliest date when a participant achieves a best overall response of sCR, CR, VGPR, or PR per 2016 IMWG criteria as determined by the IRC.

    Time frame: Up to 15 years

  6. Duration of response (DOR)

    DOR is derived only among participants who experience an overall response (sCR, CR, VGPR, or PR) per the 2016 IMWG criteria and is defined as the time from first overall response to disease progression per the 2016 IMWG criteria as determined by the IRC, or death from any cause, whichever occurs first.

    Time frame: Up to 15 years

  7. Time to Progression (TTP)

    TTP is defined as the time from randomization to the first documented disease progression per the 2016 IMWG criteria as determined by the IRC, or death due to disease progression, whichever occurs first.

    Time frame: Up to 15 years

  8. Percentage of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: Enrollment up to 15 years

  9. Percentage of Participants Experiencing Adverse Events (AEs)

    Time frame: Enrollment up to 15 years

  10. Percentage of Participants With Anti-Anitocabtagene Autoleucel Chimeric Antigen Receptor (CAR) Antibodies (Anitocabtagene Autoleucel Arm B)

    Time frame: Up to 15 years

  11. Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score

    The EORTC-QLQ-C30 is a multi-item questionnaire measuring the following content: five (5) multi-item functional scales, three (3) multi-item symptom scales, six (6) single item symptoms scales, and one combined global health status/global quality of life (QoL) scale. Each scale is measured from 0 to 100 after a linear transformation. Higher scores for functioning scales and for the Global Health Status /Global QoL scale indicate a higher level of functioning and a better QoL (ie, a better state of the participant), respectively, whereas higher scores in symptom scales represent a higher level of symptoms (ie, a worse state of the participant).

    Time frame: Baseline, up to 15 years

  12. Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) - Multiple Myeloma Module (EORTC QLQ-MY20) Scores

    The EORTC QLQ-MY20 has 20 items across 4 independent subscales; 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment) with a recall period of one week. Scores from each subscale are transformed from 0 to 100. For the functional scales, high scores represent improvement. For the symptom scales, higher scores represent worsening.

    Time frame: Baseline, up to 15 years

  13. Change From Baseline in the European Quality of Life (EuroQoL) 5-Dimension 5-Level (EQ-5D-5L) Scale Index Score

    The EQ-5D-5L includes a descriptive system that assesses health status across five dimensions that can be used to derive a single index score by applying a tariff based on health-state valuations. The index score typically ranges from 0 to 1, with higher values indicating better health status.

    Time frame: Baseline, up to 15 years

  14. Change From Baseline in the EQ-5D-5L Visual Analog Scale (VAS) Score

    The EQ-5D-5L includes a VAS that assesses self-rated current health status on a scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine"), with higher scores indicating better self-rated health.

    Time frame: Baseline, up to 15 years

  15. Percentages of Participants Responses for Patient Global Impression Scale - Severity (PGI-S)

    The PGI-S is a single-item measure that assesses a patient's perception of disease symptom severity at a point in time using a 5-point response scale ranging from "none" to "very severe."

    Time frame: Up to 15 years

  16. Percentages of Participants Responses for Patient Global Impression Scale Change (PGI-C)

    The PGI-C is a single-item measure that evaluates patients' perceptions of change in their symptoms over time using a 7-point response scale ranging from "very much worse" to "very much improved."

    Time frame: Up to 15 years

  17. Percentages of Participants Responses for Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5)

    The FACT-GP5 is a single-item question for assessing global treatment side effect bother from a patient's perspective ranging from "not at all" to "very much."

    Time frame: Up to 15 years

  18. Percentage of Participants With Hospitalizations

    Time frame: Up to 15 years

  19. Mean Number of Inpatient Days per Hospitalizations

    Time frame: Up to 15 years

  20. Mean Number of Intensive Care Unit Days per Hospitalizations

    Time frame: Up to 15 years

  21. Percentage of Participants by Reason for Hospitalization

    Time frame: Up to 15 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Mar 2039, 145 months later.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 145 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 29, 2026
StartEst.
Feb 2027
Primary completionEst.
Mar 2039
CompletionEst.
Mar 2042
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 2 other changes: verification date and references
  2. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07903506
Responsible party
Sponsor
First posted
Oct 29, 2026
Start date
Feb 2027 (estimated)
Primary completion
Mar 2039 (estimated)
Completion
Mar 2042 (estimated)
Last update
Nov 16, 2026

Study contacts

Medical Information
Contact
medinfo@kitepharma.com
844-454-5483(1-844-454-KITE)
Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anitocabtagene autoleucel

Start the discussion